Here is a comprehensive clinical overview of ICD insertion:
Implantable Cardioverter-Defibrillator (ICD) Insertion
What Is an ICD?
An ICD is an implanted device that monitors cardiac rhythm and delivers electrical therapy (shocks or antitachycardia pacing) to terminate life-threatening ventricular arrhythmias. All ICDs also function as ventricular pacemakers. The device consists of:
- A power source (lithium-based battery, lasts 5-10 years; longevity depends on shock frequency)
- Electronic circuitry with storage/remote monitoring capability
- A transvenous lead system (right ventricular lead for sensing, pacing, and shock delivery)
A biphasic waveform is the preferred waveform for internal defibrillation - it is more effective at lower energies than monophasic waveforms.
Indications
Class I (Recommended)
- Survivors of cardiac arrest from VF or hemodynamically unstable sustained VT not due to reversible causes (with >1 year meaningful survival expected)
- Structural heart disease with spontaneous sustained VT (hemodynamically stable or unstable)
- Syncope of undetermined origin with inducible sustained VT/VF at electrophysiologic study
- LVEF <35% due to prior MI - at least 40 days post-MI, 90 days post-revascularization, NYHA class II or III
- Nonischemic dilated cardiomyopathy with LVEF <35% and NYHA class II or III
- LV dysfunction post-MI with LVEF <30%, NYHA class I (40 days post-MI, 90 days post-revascularization)
- Nonsustained VT with prior MI, LVEF <40%, inducible VF/VT at EP study
- Long QT syndrome with syncope and/or VT while on beta-blockers
- Catecholaminergic polymorphic VT with syncope/sustained VT on beta-blockers
- Spontaneous type 1 Brugada pattern with sustained VA or syncope from presumed VA
Class IIa (Reasonable)
- Unexplained syncope + significant LV dysfunction + nonischemic dilated cardiomyopathy
- Sustained VT with normal/near-normal ventricular function
- NYHA class IV patients as bridge to transplant or LVAD (>1 year survival expected)
- Nonischemic cardiomyopathy from Lamin A/C mutation with ≥2 risk factors
- Hypertrophic cardiomyopathy with ≥1 major SCD risk factor
- Arrhythmogenic RV dysplasia/cardiomyopathy with syncope
- Cardiac sarcoidosis, giant-cell myocarditis, or Chagas disease
Class IIb (May Be Considered)
- Nonischemic heart disease, LVEF <35%, NYHA class I
- Long QT syndrome with SCD risk factors
- Syncope + advanced structural heart disease with unexplained cause
- Familial cardiomyopathy associated with sudden death
- LV noncompaction
Class III (Not Indicated)
- Life expectancy <1 year or poor functional status
- Incessant VT/VF (insufficient arrhythmia control)
- Significant psychiatric illness that would preclude follow-up
- NYHA class IV drug-refractory heart failure without transplant/LVAD candidacy
- Syncope in patients with no inducible VT and no structural heart disease
Device Types
| Type | Description |
|---|
| Single-chamber ICD | RV lead only - sensing, pacing, shock |
| Dual-chamber ICD | RV + RA leads - added atrial sensing for SVT discrimination |
| CRT-D | Biventricular pacing + defibrillation - for LVEF <35% with wide QRS (LBBB) |
| S-ICD | Totally subcutaneous - no transvenous leads; no pacing capability |
The Procedure
Historical Context
- 1970s-80s: Required thoracotomy for epicardial patch placement under general anesthesia with one-lung ventilation
- Modern era: Percutaneous transvenous lead placement has replaced epicardial approaches
Technique
- Venous access - typically subclavian or cephalic vein (pneumothorax is a recognized complication of subclavian access)
- Lead placement - RV lead advanced under fluoroscopy to RV apex or septum; RA lead added if dual-chamber
- Pocket creation - generator placed in subcutaneous or submuscular infraclavicular pocket
- Device testing - VT/VF is induced; cardioversion/defibrillation thresholds (DFT) are tested; shock strength programmed above minimum required
- ATP programming - antitachycardia pacing set up for VT zones (interrupts reentry circuit without shock)
- VF management: device can deliver up to 5 additional shocks if the first shock fails
Anesthesia Options
Monitored Anesthesia Care (MAC)
- Local anesthesia + IV sedation (midazolam + fentanyl)
- Monitoring: pulse oximetry, 5-lead ECG, NIBP
- Deep sedation required for device testing (shocks are painful)
General Anesthesia
- Preferred in patients with: EF <30%, CHF, CAD, pulmonary hypertension, CKD, valvular disease, or those who cannot lie flat
- Additional monitoring: arterial line may be added
- External defibrillator pads required for all ICD placements (backup if implanted device fails)
- Must be vigilant for complications: MI, stroke, cardiac perforation/tamponade, pneumothorax
Preoperative Evaluation
- EP studies to characterize arrhythmia type
- Optimize CHF/hemodynamic status preoperatively
- Patients often present with EF <30% and may require vasopressors during procedure
- Electrophysiologic studies may define VT morphology and substrate
Complications of Implantation
Similar to permanent pacemaker complications, though infection risk is slightly higher:
- Infection (up to 11.7% with repeated instrumentation/device revisions)
- Pneumothorax (subclavian access)
- Cardiac perforation/tamponade
- Pocket hematoma
- Lead dislodgement
- Venous thrombosis
ICD Malfunction (Post-implant)
Common presentations:
- Increase/change in shock frequency
- Inappropriate shocks (SVT sensed as VT, oversensing of T waves, noncardiac signals)
- Syncope, near-syncope, dizziness (undersensing of VT/VF)
- "Phantom shock" - sensation without device evidence (~10% of patients; associated with PTSD)
Management of inappropriate shocks:
- Magnet application: temporarily disables ATP and defibrillation; switches pacemaker to asynchronous mode (AOO/VOO/DOO)
- Device interrogation to identify cause
Lead Extraction
Indications (patient-related): Infection, ineffective therapy (high DFT), perforation, migration, embolization, arrhythmia induction, venous thrombosis, device upgrade
Indications (lead-related): Lead recall, lead failure, lead interactions
Technique: Powered sheaths using excimer laser or electrocautery to burn through adherent scar tissue
Anesthesia: General anesthesia with invasive monitoring is prudent given the risk of:
- Lead fracture, venous/myocardial rupture, tamponade
- Small but real chance of requiring emergent cardiac surgery
Postoperative Care
- Continuous monitoring in PACU (especially in patients with EF <30%)
- Watch for early lead dislodgement and pocket complications
- Remote device monitoring available on most modern ICDs
- Patients should be counseled about activity restrictions and driving limitations per institutional/guideline protocols
Sources: ROSEN's Emergency Medicine, 10e - Fuster and Hurst's The Heart, 15th ed - Miller's Anesthesia, 10e